Germline gain-of-function mutations in SOS1 cause Noonan syndrome.

Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev (2009) 5.53

Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer (2010) 3.59

Membrane-dependent signal integration by the Ras activator Son of sevenless. Nat Struct Mol Biol (2008) 2.82

Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev (2010) 2.68

Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68

Noonan syndrome. Lancet (2013) 2.13

The RASopathies. Annu Rev Genomics Hum Genet (2013) 2.06

Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet (2007) 1.89

New perspectives for the elucidation of genetic disorders. Am J Hum Genet (2007) 1.89

Molecular mechanisms in signal transduction at the membrane. Nat Struct Mol Biol (2010) 1.86

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84

Mitogen-activated protein kinases in heart development and diseases. Circulation (2007) 1.84

Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab (2011) 1.82

Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal (2009) 1.79

Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res (2008) 1.77

Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet (2013) 1.71

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer (2008) 1.66

A rasopathy phenotype with severe congenital hypertrophic obstructive cardiomyopathy associated with a PTPN11 mutation and a novel variant in SOS1. Am J Med Genet A (2012) 1.62

Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol (2010) 1.60

Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci (2010) 1.54

Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Hum Genet (2010) 1.53

Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat (2009) 1.49

Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest (2007) 1.48

Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. Chem Biol (2014) 1.45

Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene (2013) 1.44

Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. Proc Natl Acad Sci U S A (2008) 1.40

Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome-like phenotype and hyperactivated MAPK signaling in humans and mice. J Clin Invest (2011) 1.39

MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39

A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest (2008) 1.38

Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects. PLoS Genet (2007) 1.37

Genetic determinants of cardiac hypertrophy. Curr Opin Cardiol (2008) 1.35

Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet (2013) 1.30

Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci (2007) 1.30

Ras and Rap signaling in synaptic plasticity and mental disorders. Neuroscientist (2010) 1.29

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet (2015) 1.24

Genetics of congenital heart disease. Curr Cardiol Rev (2010) 1.23

Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell (2010) 1.22

Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur J Hum Genet (2009) 1.22

Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless. Proc Natl Acad Sci U S A (2010) 1.22

Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1. Elife (2013) 1.22

Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation. J Clin Invest (2010) 1.21

Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects. Dis Model Mech (2011) 1.18

Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci U S A (2014) 1.17

Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome. Br J Dermatol (2011) 1.13

SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mutat (2011) 1.12

Of mice and men: molecular genetics of congenital heart disease. Cell Mol Life Sci (2013) 1.10

Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol (2011) 1.08

SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet (2007) 1.08

Cardio-facio-cutaneous syndrome: does genotype predict phenotype? Am J Med Genet C Semin Med Genet (2011) 1.08

Quantitative trait loci for aggressive behavior in Drosophila melanogaster. Genetics (2009) 1.08

RASopathies: Clinical Diagnosis in the First Year of Life. Mol Syndromol (2011) 1.07

Mammalian son of sevenless Guanine nucleotide exchange factors: old concepts and new perspectives. Genes Cancer (2011) 1.04

Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet (2014) 1.04

The face of Noonan syndrome: Does phenotype predict genotype. Am J Med Genet A (2010) 1.03

Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol Cell Biol (2010) 1.02

NMR-based functional profiling of RASopathies and oncogenic RAS mutations. Proc Natl Acad Sci U S A (2013) 1.02

De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet (2007) 1.02

PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link? Pediatr Cardiol (2009) 1.01

SOS1 and PTPN11 mutations in five cases of Noonan syndrome with multiple giant cell lesions. Eur J Hum Genet (2009) 1.01

PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots? Trends Cardiovasc Med (2011) 1.00

Retracted A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J Biol Chem (2013) 1.00

What's new in the neuro-cardio-facial-cutaneous syndromes? Eur J Pediatr (2007) 0.99

Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genet Med (2008) 0.98

Allosteric gating of Son of sevenless activity by the histone domain. Proc Natl Acad Sci U S A (2010) 0.98

A suggested role for mitochondria in Noonan syndrome. Biochim Biophys Acta (2009) 0.97

Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations. J Biol Chem (2013) 0.97

Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling. J Invest Dermatol (2010) 0.97

Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J Biol Chem (2009) 0.96

Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav (2008) 0.96

Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol (2010) 0.95

Regulation of ras exchange factors and cellular localization of ras activation by lipid messengers in T cells. Front Immunol (2013) 0.95

RAS diseases in children. Haematologica (2014) 0.95

ErbB signaling in cardiac development and disease. Semin Cell Dev Biol (2010) 0.95

Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome. Eur J Hum Genet (2008) 0.94

SUMOylation of Grb2 enhances the ERK activity by increasing its binding with Sos1. Mol Cancer (2014) 0.92

Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur J Hum Genet (2013) 0.92

Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am J Med Genet A (2009) 0.89

Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy? Clin Genet (2013) 0.89

Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. Hum Mutat (2015) 0.88

Tumor development in three patients with Noonan syndrome. Eur J Pediatr (2007) 0.88

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol Med (2012) 0.88

Differences in flexibility underlie functional differences in the Ras activators son of sevenless and Ras guanine nucleotide releasing factor 1. Structure (2009) 0.88

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov (2016) 0.88

Lens induction requires attenuation of ERK signaling by Nf1. Hum Mol Genet (2011) 0.87

Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol (2012) 0.87

Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations. Am J Med Genet A (2010) 0.86

Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations. Mol Syst Biol (2014) 0.86

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol (2014) 0.86

The role of ultrasound in the diagnosis of fetal genetic syndromes. Best Pract Res Clin Obstet Gynaecol (2014) 0.85

Pivotal role of the muscle-contraction pathway in cryptorchidism and evidence for genomic connections with cardiomyopathy pathways in RASopathies. BMC Med Genomics (2013) 0.84

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry (2014) 0.84

SHP-2 tyrosine phosphatase in human diseases. Int J Clin Exp Med (2009) 0.84

Evolutionary analyses of entire genomes do not support the association of mtDNA mutations with Ras/MAPK pathway syndromes. PLoS One (2011) 0.83

The language phenotype of children and adolescents with Noonan syndrome. J Speech Lang Hear Res (2010) 0.83

Genetic approaches for changing the heart and dissecting complex syndromes. J Mol Cell Cardiol (2008) 0.82

NRAS Mutations in Noonan Syndrome. Mol Syndromol (2012) 0.82

LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria. Eur J Pediatr (2011) 0.82

Genetic predispositions to childhood leukemia. Ther Adv Hematol (2013) 0.82

Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr (2008) 0.82

Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15

The diploid genome sequence of an Asian individual. Nature (2008) 46.29

A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78

Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05

The sequence and de novo assembly of the giant panda genome. Nature (2009) 15.76

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43

Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol (2008) 8.92

The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19

An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94

ZDOCK: an initial-stage protein-docking algorithm. Proteins (2003) 7.52

salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell (2002) 7.15

Gene discovery and annotation using LCM-454 transcriptome sequencing. Genome Res (2006) 7.10

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08

A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. Hum Mol Genet (2003) 6.82

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30

PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data. Nucleic Acids Res (2003) 6.19

The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev (2010) 6.05

SNP discovery via 454 transcriptome sequencing. Plant J (2007) 5.92

MicroRNA-mediated conversion of human fibroblasts to neurons. Nature (2011) 5.59

Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev (2010) 5.38

The oyster genome reveals stress adaptation and complexity of shell formation. Nature (2012) 5.30

STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature (2003) 5.27

A porous supramolecular architecture from a copper(II) coordination polymer with a 3D four-connected 8(6) net. Inorg Chem (2003) 5.16

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09

Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J Exp Med (2007) 4.95

Stability of the regulatory T cell lineage in vivo. Science (2010) 4.89

Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med (2007) 4.80

The Plasmodium genome database. Nature (2002) 4.36

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11

Mathematical models of protein kinase signal transduction. Mol Cell (2002) 4.08

Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood (2003) 3.98

Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr (2004) 3.96

Genomic analysis reveals that Pseudomonas aeruginosa virulence is combinatorial. Genome Biol (2006) 3.75

Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med (2006) 3.66

PTP1B regulates leptin signal transduction in vivo. Dev Cell (2002) 3.61

Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55

Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev (2012) 3.48

ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Res (2003) 3.24

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20

Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev (2011) 3.15

Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science (2002) 3.12

A mouse knockout library for secreted and transmembrane proteins. Nat Biotechnol (2010) 3.09

Gene density, transcription, and insulators contribute to the partition of the Drosophila genome into physical domains. Mol Cell (2012) 3.08

Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol (2003) 3.02

Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology (2002) 2.96

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol (2012) 2.91

Endothelial and hematopoietic cell fate of human embryonic stem cells originates from primitive endothelium with hemangioblastic properties. Immunity (2004) 2.89

Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity (2009) 2.84

Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 2.84

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell (2004) 2.82

PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet (2002) 2.81

The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev (2008) 2.74

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71

A highly sensitive CMOS digital Hall sensor for low magnetic field applications. Sensors (Basel) (2012) 2.69

Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69

PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem (2005) 2.68

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68

Mutations in myosin light chain kinase cause familial aortic dissections. Am J Hum Genet (2010) 2.67

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65

Genomic characterization of non-O1, non-O139 Vibrio cholerae reveals genes for a type III secretion system. Proc Natl Acad Sci U S A (2005) 2.65

Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis (2009) 2.62

A review of EPAP nasal device therapy for obstructive sleep apnea syndrome. Sleep Breath (2014) 2.61

Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60

Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59

The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Mol Cell Biol (2008) 2.57

Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. Circulation (2010) 2.57

A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun (2005) 2.55

Tumor-initiating cells are rare in many human tumors. Cell Stem Cell (2010) 2.54

The mitochondrial inner membrane protein mitofilin controls cristae morphology. Mol Biol Cell (2005) 2.53

The "Gab" in signal transduction. Trends Cell Biol (2003) 2.52

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51

Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. Kidney Int (2011) 2.50

AILUN: reannotating gene expression data automatically. Nat Methods (2007) 2.47

High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer (2008) 2.46

1,1'-[(Hexane-1,6-diyldi-oxy)bis-(nitrilo-methyl-idyne)]dinaphthalene. Acta Crystallogr Sect E Struct Rep Online (2008) 2.45

Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med (2005) 2.42

Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell (2002) 2.42

Selective sphingosine 1-phosphate 1 receptor activation reduces ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol (2006) 2.39

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Diethyl 3,8-dimethyl-4,7-diazadeca-2,8-dienedioate. Acta Crystallogr C (2004) 2.38

HIV/STD stigmatization fears as health-seeking barriers in China. AIDS Behav (2006) 2.37

PlasmoDB: the Plasmodium genome resource. An integrated database providing tools for accessing, analyzing and mapping expression and sequence data (both finished and unfinished). Nucleic Acids Res (2002) 2.37

Inflammation in acute kidney injury. Nephron Exp Nephrol (2008) 2.32

Analysis of congenital hypomyelinating Egr2Lo/Lo nerves identifies Sox2 as an inhibitor of Schwann cell differentiation and myelination. Proc Natl Acad Sci U S A (2005) 2.29

B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity (2007) 2.28

Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol (2011) 2.27

Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A (2007) 2.27

Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol (2011) 2.27

TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell (2008) 2.26

2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-yl N-ethyl-carbamate. Acta Crystallogr Sect E Struct Rep Online (2009) 2.24

Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol (2006) 2.22